TIS tissue therapies limited

a selling opportunity, page-7

  1. 2,630 Posts.
    lightbulb Created with Sketch. 4
    spp most likely as cheaper to deal with (imo) - although not so equitable.
    Supporting this - all appears to be going well, or at least as well as late stage biotech's ever go when getting through the regulatory maze prior to production.

    I am not an analyst - dyor
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.